JPH11508577A - 抗菌活性物質及び徐放性パントプラゾールを含有する経口医薬品 - Google Patents
抗菌活性物質及び徐放性パントプラゾールを含有する経口医薬品Info
- Publication number
- JPH11508577A JPH11508577A JP9504811A JP50481197A JPH11508577A JP H11508577 A JPH11508577 A JP H11508577A JP 9504811 A JP9504811 A JP 9504811A JP 50481197 A JP50481197 A JP 50481197A JP H11508577 A JPH11508577 A JP H11508577A
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- pantoprazole
- pharmaceutical product
- oral pharmaceutical
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.少なくとも1種の抗菌活性成分と組み合わされたパントプラゾールからな るヘリコバクターに起因する疾患を治療するための経口医薬品において、少なく とも一部のパントプラゾールが徐放形であることを特徴とする、少なくとも1種 の抗菌活性成分と組み合わされたパントプラゾールからなるヘリコバクターに起 因する疾患を治療するための経口医薬品。 2.完全に又は部分的に徐放形のパントプラゾールが、単一投与単位で少なく とも1種の抗菌活性成分と固定的に組み合わされている、請求項1に記載の経口 医薬品。 3.パントプラゾールがペレット形で、少なくとも1種の抗菌活性成分と一緒 に投与単位としての1つのカプセル中に存在する、請求項2に記載の経口医薬品 。 4.完全に又は部分的に徐放形のパントプラゾールが、少なくとも1種の抗菌 活性成分と一緒に、多層錠剤中に存在する、請求項2に記載の経口医薬品。 5.パントプラゾール及び少なくとも1種の抗菌活性成分が別々の投与単位で 、単一包装中に存在する、請求項1に記載の経口医薬品。 6.単一包装が、用法用量が患者に通ずるような投与単位の個々の成分の相対 的アレンジにより、薬名分 量により、かつ/又は着色によりデザインされているブリスターパックである、 請求項5に記載の経口医薬品。 7.パントプラゾールの徐放形がアルカリ性ペレット又は錠剤核、活性成分の 放出を制御する少なくとも1つの中間層及び小腸で可溶性の外側腸溶層を有する 、請求項1に記載の経口医薬品。 8.少なくとも1つの中間層が水不溶性徐放性被膜形成剤からなる、請求項7 に記載の経口医薬品。 9.被膜形成剤が溶液又は分散液から施与されている、請求項8に記載の経口 医薬品。 10.中間層が水不溶性徐放性被膜形成剤として、水不溶性セルロースエーテル 及び/又は酢酸ポリビニルを含有する、請求項8に記載の経口医薬品。 11.中間層が水不溶性徐放性被膜形成剤として、エチルセルロース、アンモニ オメタクリレートコポリマー(EudragitTRRS、EudragitTRRL)又はポリビニルアル コールを含有する、請求項8に記載の経口医薬品。 12.小腸で可溶性の外側腸溶層がメタクリル酸/メタクリル酸メチルコポリマ ー又はメタクリル酸/メタクリル酸エチルコポリマー(EudragitTRL)からなる、 請求項11に記載の経口医薬品。 13.外側腸溶層がセルロース誘導体被覆からなる、請求項7に記載の経口医薬 品。 14.セルロース誘導体が、カルボキシメチルエチル セルロース、酢酸フタル酸セルロース、酢酸トリメリト酸セルロース、ヒドロキ シプロピルメチルセルロースフタレート及びヒドロキシプロピルメチルセルロー スアセテートスクシネートからなる群から選択されるいずれかである、請求項1 3に記載の経口医薬品。 15.空孔形成剤、可塑剤、緩衝剤、塩基及び顔料からなる群から選択されるい ずれかが付加的に中間層中に存在する、請求項7に記載の経口医薬品。 16.抗菌活性成分が、次クエン酸ビスマス、次サリチル酸ビスマス、ニトロフ ラゾン、ニトロフラントイン、フラゾリドン、メトロニダゾル、チニダゾール、 ニモラゾール、ゲンタマイシン、ネオマイシン、カナマイシン、アミカシン、ス トレプトマイシン、エリスロマイシン、アジスロマイシン、クラリスロマイシン 、クリンダマイシン、リファンピシン、ペニシリンG、ペニシリンV、アンピシ リン、メズロシリン、アモキシシリン、バシトラシン、ポリミキシン、テトラシ リン、クロロテトラサイクリン、オキシテトラサイクリン、ミノサイクリン、ド キシサイクリン、イミペネム、ロラカルベフ、メロペネム、パニペネム、セファ レキシン、セホキシチン、セフロキシムアクセチル、セフォタキシム、セフポド キシムプロキセチル、セファクロール、セファドロキシル、セファロチン、シプ ロフロキサシン、ノルフロキサシン、オフロキサシン、ペフロキサシン及びクロ ラムフェニコールからなる 群から選択されるいずれかである、請求項1に記載の医薬品。 17.パントプラゾールを少なくとも1種の抗菌活性成分と組み合わせて、ヘリ コバクターに起因する疾患を治療するための医薬品を製造するために使用するこ とにおいて、パントプラゾールの少なくとも一部が徐放形である、パントプラゾ ールの使用。 18.ヘリコバクターに起因する疾患を治療するために、活性成分としてのパン トプラゾールのための、又はそれと少なくとも1種の抗菌活性成分との複合使用 のためのペレット又は錠剤形の経口医薬品を製造する方法において、その方法が 、a)活性成分をアルカリ塩として、かつ/又はアルカリ性物質を添加してペレ ット又は錠剤核にし、b)これに、主に水不溶性徐放性酸性被膜形成剤からなる 少なくとも1つの徐放性中間層を施与し、c)次いで、小腸で可溶性の外側腸溶 層を施与することからなることを特徴とする、ヘリコバクターに起因する疾患を 治療するために、活性成分としてのパントプラゾールのための、又はそれと少な くとも1種の抗菌活性成分との複合使用のためのペレット又は錠剤形の経口医薬 品を製造する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/498,386 US5945124A (en) | 1995-07-05 | 1995-07-05 | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
US08/498,386 | 1995-07-05 | ||
PCT/EP1996/002892 WO1997002020A1 (en) | 1995-07-05 | 1996-07-02 | Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11508577A true JPH11508577A (ja) | 1999-07-27 |
Family
ID=23980878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9504811A Pending JPH11508577A (ja) | 1995-07-05 | 1996-07-02 | 抗菌活性物質及び徐放性パントプラゾールを含有する経口医薬品 |
Country Status (14)
Country | Link |
---|---|
US (3) | US5945124A (ja) |
EP (2) | EP1213015B1 (ja) |
JP (1) | JPH11508577A (ja) |
AT (2) | ATE232090T1 (ja) |
AU (1) | AU6517496A (ja) |
CA (2) | CA2587000A1 (ja) |
CY (1) | CY2459B1 (ja) |
DE (2) | DE69626116T2 (ja) |
DK (2) | DK1213015T3 (ja) |
ES (2) | ES2263700T3 (ja) |
HK (1) | HK1010836A1 (ja) |
PT (2) | PT841903E (ja) |
SI (1) | SI0841903T1 (ja) |
WO (1) | WO1997002020A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002234842A (ja) * | 2001-02-09 | 2002-08-23 | Kyowa Yakuhin Kogyo Kk | 内服腸溶性製剤 |
WO2009069280A1 (ja) * | 2007-11-27 | 2009-06-04 | Ohara Pharmaceutical Co., Ltd. | 造粒物の製造法 |
WO2014136494A1 (ja) * | 2013-03-08 | 2014-09-12 | 富士フイルム株式会社 | 腸溶性細粒及び医薬組成物 |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1092434T3 (da) * | 1995-09-21 | 2004-07-26 | Pharma Pass Ii Llc | Hidtil ukendt sammensætning indeholdende lansoprazol og fremgangsmåde til fremstilling deraf |
US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SE9602442D0 (sv) * | 1996-06-20 | 1996-06-20 | Astra Ab | Administration of pharmaceuticals |
SE9700885D0 (sv) * | 1997-03-12 | 1997-03-12 | Astra Ab | New pharmaceutical formulation |
US6197331B1 (en) | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
ATE281178T1 (de) * | 1997-07-25 | 2004-11-15 | Altana Pharma Ag | Protonenpumpenhemmer als kombinationstherapeutika mit antibakterielle wirkenden substanzen |
DE19732903A1 (de) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
ES2137862B1 (es) * | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
ATE238774T1 (de) * | 1997-10-09 | 2003-05-15 | Dexcel Pharma Technologies Ltd | Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt |
SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
WO1999043327A1 (fr) * | 1998-02-24 | 1999-09-02 | Kaneka Corporation | Compositions antimicrobiennes a effet synergique, medicaments et remedes pour maladies digestives contenant ces compositions, leur procede de production et preparations associees |
WO1999051270A1 (en) * | 1998-04-06 | 1999-10-14 | Dalhousie University | A novel nitroreductase and therapeutic uses therefor |
DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
US7122207B2 (en) * | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
AU772726B2 (en) * | 1998-08-12 | 2004-05-06 | Takeda Gmbh | Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles |
US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
DE19850445A1 (de) * | 1998-11-02 | 2000-05-04 | Falk Pharma Gmbh | Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen |
ATE271556T1 (de) * | 1998-11-18 | 2004-08-15 | Astrazeneca Ab | Verbesserter chemischer prozess und eine pharmazeutische zubereitung |
US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
ES2168043B1 (es) * | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
MXPA02004293A (es) | 1999-10-29 | 2002-10-31 | Euro Celtique Sa | Formulaciones de hidrocodona de liberacion controlada.. |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
DE10030318C1 (de) * | 2000-06-27 | 2002-02-28 | Byk Gulden Lomberg Chem Fab | Arzneimittelverpackung für die Eradikationstherapie |
US20020064555A1 (en) * | 2000-09-29 | 2002-05-30 | Dan Cullen | Proton pump inhibitor formulation |
US20020068078A1 (en) | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
CN100518827C (zh) | 2000-10-30 | 2009-07-29 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
EP1341524B1 (en) * | 2000-12-07 | 2011-10-19 | Nycomed GmbH | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
AU4061702A (en) * | 2001-05-15 | 2003-04-03 | Mcneil-Ppc, Inc. | Dip coating compositions containing starch or dextrin |
US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
DE60233874D1 (de) | 2001-06-22 | 2009-11-12 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
TNSN03137A1 (en) * | 2001-06-22 | 2005-12-23 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS COMPRISING LOW SOLUBILITY AND / OR ACID SENSITIVE DRUGS AND NEUTRALIZED ACID POLYMERS. |
US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
FR2830447B1 (fr) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
JP2005521662A (ja) * | 2002-01-25 | 2005-07-21 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤の経粘膜送達 |
DE10211289A1 (de) * | 2002-03-14 | 2003-09-25 | Basf Ag | Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität |
US20030175342A1 (en) * | 2002-03-14 | 2003-09-18 | Karl Kolter | Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate |
CA2480824A1 (fr) * | 2002-04-09 | 2003-10-16 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline |
WO2003084518A2 (fr) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules de principes actifs |
US7125563B2 (en) | 2002-04-12 | 2006-10-24 | Dava Pharmaceuticals, Inc. | Sustained release pharmaceutical preparations and methods for producing the same |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
EP1519717B1 (en) * | 2002-07-05 | 2010-09-29 | Temrel Limited | Controlled release composition |
WO2004009059A1 (en) * | 2002-07-19 | 2004-01-29 | Aventis Pharma S.A. | Taste masked oral composition of telithromycin |
US20040013737A1 (en) * | 2002-07-19 | 2004-01-22 | Philippe Becourt | Taste masked oral composition of telithromycin |
CA2488860A1 (en) * | 2002-07-25 | 2004-02-05 | Pharmacia Corporation | Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former |
US7429619B2 (en) * | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
US20040028737A1 (en) * | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
AU2003250468A1 (en) * | 2002-08-16 | 2004-03-03 | Themis Laboratories Private Limited | A process for manufacture of stable oral multiple units pharamceutical composition containing benzimidazoles |
US20050191353A1 (en) * | 2002-08-16 | 2005-09-01 | Amit Krishna Antarkar | Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles |
SE0203065D0 (sv) * | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
ES2534713T3 (es) * | 2002-10-16 | 2015-04-27 | Takeda Pharmaceutical Company Limited | Preparaciones sólidas estables |
MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
AU2003284942A1 (en) * | 2002-10-30 | 2004-06-07 | Pharmacia Corporation | Oral extended release tablets and methods of making and using the same |
WO2004058228A1 (en) * | 2002-12-24 | 2004-07-15 | Lupin Limited | Enteric coated fluoxetine composition |
US20040146558A1 (en) * | 2003-01-28 | 2004-07-29 | Kyowa Pharmaceutical Co., Ltd. | Oral enteric-coated preparation |
WO2004073654A2 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid |
EP1602362B1 (en) * | 2003-03-12 | 2016-09-28 | Takeda Pharmaceutical Company Limited | Drug composition having active ingredient adhered at high concentration to spherical core |
JP2006522099A (ja) * | 2003-04-04 | 2006-09-28 | ファルマシア コーポレーション | 複合粒状体からなる経口徐放性圧縮錠 |
BR0300882A (pt) * | 2003-04-09 | 2005-05-10 | Cmax Otimizacao De Resultados | Composições farmacêuticas, método e uso de formulação para tratamento e prevenção de infecções associadas com helicobacter pylori em mamìferos e no ser humano |
PE20050150A1 (es) | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
CL2004000983A1 (es) | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
US8986736B2 (en) * | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
CA2529984C (en) | 2003-06-26 | 2012-09-25 | Isa Odidi | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
RU2375048C2 (ru) * | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
EP1648407A4 (en) | 2003-07-21 | 2011-08-31 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, CORRESPONDING USE AND FORMULATION |
JP2006528189A (ja) | 2003-07-21 | 2006-12-14 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質産物、その使用法および製剤 |
WO2005009364A2 (en) | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
EP1653925A1 (en) | 2003-08-11 | 2006-05-10 | Advancis Pharmaceutical Corporation | Robust pellet |
JP2007502294A (ja) | 2003-08-12 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
EP1658034A4 (en) * | 2003-08-29 | 2011-06-22 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION |
CA2536902A1 (en) * | 2003-09-03 | 2005-03-10 | Agi Therapeutics Limited | Proton pump inhibitor formulations, and methods of preparing and using such formulations |
CA2538064C (en) | 2003-09-15 | 2013-12-17 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
US8168228B2 (en) | 2003-10-17 | 2012-05-01 | Sandoz Ag | Antibiotic clarithromycin micropellet compositions |
DE10353186A1 (de) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
WO2005051362A2 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating |
US20050181052A1 (en) * | 2004-02-17 | 2005-08-18 | Patel Satishkumar A. | Lansoprazole microtablets |
RS52233B (en) * | 2004-05-07 | 2012-10-31 | Nycomed Gmbh | THE PHARMACEUTICAL DOSAGE FORM CONTAINING GRANULES AND ITS PRODUCTION PROCEDURE |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
AU2005264864B2 (en) | 2004-06-16 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Multiple PPI dosage form |
WO2006014427A1 (en) | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
DE102004035936A1 (de) * | 2004-07-23 | 2006-03-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform |
US10624858B2 (en) * | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
WO2006026829A1 (en) * | 2004-09-09 | 2006-03-16 | Metelli Pty Ltd | Stable paste composition of enteric coated acid labile active agent and use thereof |
AR051654A1 (es) * | 2004-11-04 | 2007-01-31 | Astrazeneca Ab | Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones |
AR052225A1 (es) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones |
WO2006067599A2 (en) | 2004-12-23 | 2006-06-29 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
US20080279951A1 (en) * | 2005-02-02 | 2008-11-13 | Rajesh Gandhi | Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process |
CN101111230B (zh) * | 2005-03-29 | 2010-05-19 | 赢创罗姆有限责任公司 | 包含对活性成分具有调节释放作用的小丸的多颗粒药用形式 |
CA2601339A1 (en) * | 2005-03-29 | 2006-10-05 | Roehm Gmbh | Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance |
EP1895990A2 (en) * | 2005-05-13 | 2008-03-12 | Combino Pharm, S.L. | Formulations containing pantoprazole free acid and its salts |
US20070087056A1 (en) * | 2005-08-09 | 2007-04-19 | Claudia Guthmann | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility |
KR100591142B1 (ko) * | 2005-11-04 | 2006-06-20 | 지엘팜텍 주식회사 | 파록세틴을 활성물질로 함유하는 장용성 서방형 정제 |
WO2007063552A1 (en) * | 2005-12-02 | 2007-06-07 | Lupin Limited | Stable taste masked formulations of cephalosporins |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
EP1803450A1 (en) * | 2006-01-03 | 2007-07-04 | Ferrer Internacional, S.A. | Pharmaceutical compositions for the eradication of helicobacter pylori |
EP1973532A1 (en) * | 2006-01-16 | 2008-10-01 | Jubilant Organosys Limited | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same |
US8088414B2 (en) * | 2006-02-07 | 2012-01-03 | Fmc Corporation | Latex or pseudolatex compositions, coatings and coating processes |
DE102006006532B4 (de) * | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
JP2009538901A (ja) * | 2006-06-01 | 2009-11-12 | デクセル ファーマ テクノロジーズ エルティーディー. | 複式ユニット製薬的製剤 |
WO2008015530A2 (en) * | 2006-08-03 | 2008-02-07 | Aurobindo Pharma Limited | Stable solid oral formulation of pantoprazole |
ES2385498T3 (es) | 2006-08-18 | 2012-07-25 | Evonik Röhm Gmbh | Composición farmacéutica con liberación controlada de la sustancia activa, para sustancias activas con una buena solubilidad en agua |
JP5629581B2 (ja) | 2007-10-12 | 2014-11-19 | タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド | 食物の摂取から独立した消化器疾患の治療方法 |
US8911787B2 (en) | 2008-02-26 | 2014-12-16 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
NZ592049A (en) * | 2008-10-03 | 2012-11-30 | Falk Pharma Gmbh | Compositions and methods for the treatment of bowel diseases with granulated mesalamine |
DE102008056312A1 (de) | 2008-11-07 | 2010-05-12 | Biogenerics Pharma Gmbh | Verwendung von Mikrotabletten als Lebens-und Futtermittelzusatz |
EP2405898A2 (en) | 2009-03-09 | 2012-01-18 | Council Of Scientific & Industrial Research | Sustained release composition of therapeutic agent |
US8663671B2 (en) | 2009-11-05 | 2014-03-04 | Philip Morris Usa Inc. | Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity |
WO2011080500A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
WO2011080502A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
US20150283083A1 (en) * | 2012-11-19 | 2015-10-08 | Azanta A/S | Dispersible Tablet |
US20140271845A1 (en) * | 2013-03-15 | 2014-09-18 | Cerovene, Inc. | Coated substrate compositions |
WO2015115586A1 (ja) * | 2014-01-31 | 2015-08-06 | 塩野義製薬株式会社 | 徐放性製剤 |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
UY39094A (es) * | 2020-02-27 | 2021-07-30 | Hk Inno N Corp | Composición farmacéutica que comprende compuesto derivado de bencimidazol |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
GB9018603D0 (en) * | 1990-08-24 | 1990-10-10 | Smith Kline French Lab | Compositions |
YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
US5582837A (en) * | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
FR2692146B1 (fr) * | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
AU6713194A (en) * | 1993-04-27 | 1994-11-21 | Sepracor, Inc. | Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
WO1995008332A1 (en) * | 1993-09-20 | 1995-03-30 | The Procter & Gamble Company | Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection |
SE9602442D0 (sv) * | 1996-06-20 | 1996-06-20 | Astra Ab | Administration of pharmaceuticals |
SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
-
1995
- 1995-07-05 US US08/498,386 patent/US5945124A/en not_active Expired - Lifetime
-
1996
- 1996-07-02 DE DE69626116T patent/DE69626116T2/de not_active Expired - Lifetime
- 1996-07-02 PT PT96924849T patent/PT841903E/pt unknown
- 1996-07-02 PT PT02005081T patent/PT1213015E/pt unknown
- 1996-07-02 WO PCT/EP1996/002892 patent/WO1997002020A1/en active IP Right Grant
- 1996-07-02 AU AU65174/96A patent/AU6517496A/en not_active Abandoned
- 1996-07-02 EP EP02005081A patent/EP1213015B1/en not_active Expired - Lifetime
- 1996-07-02 JP JP9504811A patent/JPH11508577A/ja active Pending
- 1996-07-02 DK DK02005081T patent/DK1213015T3/da active
- 1996-07-02 EP EP96924849A patent/EP0841903B1/en not_active Expired - Lifetime
- 1996-07-02 SI SI9630595T patent/SI0841903T1/xx unknown
- 1996-07-02 CA CA002587000A patent/CA2587000A1/en not_active Abandoned
- 1996-07-02 DE DE69636104T patent/DE69636104T2/de not_active Expired - Lifetime
- 1996-07-02 AT AT96924849T patent/ATE232090T1/de not_active IP Right Cessation
- 1996-07-02 ES ES02005081T patent/ES2263700T3/es not_active Expired - Lifetime
- 1996-07-02 DK DK96924849T patent/DK0841903T3/da active
- 1996-07-02 AT AT02005081T patent/ATE324872T1/de not_active IP Right Cessation
- 1996-07-02 CA CA002232450A patent/CA2232450C/en not_active Expired - Fee Related
- 1996-07-02 ES ES96924849T patent/ES2192226T3/es not_active Expired - Lifetime
-
1998
- 1998-03-13 US US09/042,090 patent/US6068856A/en not_active Expired - Lifetime
- 1998-11-20 HK HK98112159A patent/HK1010836A1/xx not_active IP Right Cessation
-
1999
- 1999-12-15 US US09/461,388 patent/US6274173B1/en not_active Expired - Lifetime
-
2004
- 2004-06-11 CY CY0400047A patent/CY2459B1/xx unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002234842A (ja) * | 2001-02-09 | 2002-08-23 | Kyowa Yakuhin Kogyo Kk | 内服腸溶性製剤 |
WO2009069280A1 (ja) * | 2007-11-27 | 2009-06-04 | Ohara Pharmaceutical Co., Ltd. | 造粒物の製造法 |
JPWO2009069280A1 (ja) * | 2007-11-27 | 2011-04-07 | 大原薬品工業株式会社 | 造粒物の製造法 |
JP2014169344A (ja) * | 2007-11-27 | 2014-09-18 | Ohara Yakuhin Kogyo Kk | 造粒物の製造法 |
WO2014136494A1 (ja) * | 2013-03-08 | 2014-09-12 | 富士フイルム株式会社 | 腸溶性細粒及び医薬組成物 |
JP5934835B2 (ja) * | 2013-03-08 | 2016-06-15 | 富士フイルム株式会社 | 腸溶性細粒及び医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2232450C (en) | 2007-09-04 |
SI0841903T1 (en) | 2003-08-31 |
US5945124A (en) | 1999-08-31 |
ES2263700T3 (es) | 2006-12-16 |
EP0841903A1 (en) | 1998-05-20 |
DE69626116D1 (de) | 2003-03-13 |
EP0841903B1 (en) | 2003-02-05 |
HK1010836A1 (en) | 1999-07-02 |
PT841903E (pt) | 2003-06-30 |
CA2232450A1 (en) | 1997-01-23 |
AU6517496A (en) | 1997-02-05 |
DK1213015T3 (da) | 2006-08-14 |
ATE232090T1 (de) | 2003-02-15 |
EP1213015A1 (en) | 2002-06-12 |
CA2587000A1 (en) | 1997-01-23 |
US6068856A (en) | 2000-05-30 |
WO1997002020A1 (en) | 1997-01-23 |
PT1213015E (pt) | 2006-09-29 |
US6274173B1 (en) | 2001-08-14 |
DE69636104T2 (de) | 2006-11-30 |
DK0841903T3 (da) | 2003-05-19 |
DE69626116T2 (de) | 2003-10-23 |
ES2192226T3 (es) | 2003-10-01 |
CY2459B1 (en) | 2005-06-03 |
DE69636104D1 (de) | 2006-06-08 |
EP1213015B1 (en) | 2006-05-03 |
ATE324872T1 (de) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11508577A (ja) | 抗菌活性物質及び徐放性パントプラゾールを含有する経口医薬品 | |
US6132768A (en) | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors | |
CA2595033C (en) | Gastroresistant pharmaceutical formulations containing rifaximin | |
JP3140764B2 (ja) | ミノサイクリンの脈動性1日1回放出系 | |
JP5162689B2 (ja) | 活性成分としてのパントプラゾールを含有する投与形 | |
GB2189698A (en) | Coated omeprazole tablets | |
JP2001525366A (ja) | 酸不安定な活性化合物を含有する新規の投与形 | |
PT1746980E (pt) | Forma de dosagem farmacêutica compreendendo granulados assim como o seu processo de fabrico | |
EP1696889A1 (en) | Pharmaceutical compositions of benzimidazole and processes for their preparation | |
JP4800926B2 (ja) | 活性成分としての(s)−パントプラゾールを含有する医薬組成物 | |
CA2984235C (en) | Rivastigmine-containing sustained-release pharmaceutical composition | |
CA2225628C (en) | Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors | |
CN114786652A (zh) | 用于治疗或预防疾病的剂型 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070326 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070827 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20070831 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071204 |